Wedbush Starts Spring Works Therapeutics (SWTX) at Outperform
- Wall Street extends rally as economically sensitive sectors bounce
- China Tells Local Authorities to Prepare For a 'Possible Storm' and Prevent Unrest as Evergrande Crisis Unravels - WSJ
- Salesforce (CRM) Raises FY22 Revenue Guidance; Initiates FY23 Revenue
- Oil prices at two-month highs on tight supplies
- IDFA Seen as a 'Real Headwind' for Facebook (FB) but Analysts Remain Positive
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Wedbush analyst David Nierengarten initiates coverage on Spring Works Therapeutics (NASDAQ: SWTX) with a Outperform rating and a price target of $33.00.
Shares of Spring Works Therapeutics closed at $18.67 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Tudor Pickering Starts Tesla (TSLA) at Sell
- UPDATE: Tudor Pickering Starts Fisker (FSR) at Buy
- BMO Capital Starts Anaergia Inc (ANRG:CN) at Outperform
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!